Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Thyroid Hormone for NASH
NCT05526144Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Apr 2023
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levothyroxine sodium in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: Improvement in Nonalcoholic fatty liver disease activity score (NAS) by 2 points at 12 months. Started Apr 2023; status: recruiting.
02
Drugs
levothyroxine sodium
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05526144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526144.